what is the rationale for novel combination therapies?
Published 7 years ago • 81 plays • Length 5:24Download video MP4
Download video MP3
Similar videos
-
3:28
the epigenetics of multiple myeloma and the rationale for hdac inhibitors
-
1:14
insights into novel agents and potential combination therapies being explored in mf
-
2:20
british society for haematology: driving a therapeutic revolution in hematology
-
4:16
novel therapies for mpns
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
1:24
novel agents for the treatment of hodgkin lymphoma: brentuximab vedotin and nivolumab
-
9:21
the evolution of treatment of ph all & phase ii study of blinatumomab and ponatinib in ph all
-
4:36
ha understanding, treating and managing haemochromatosis - current research and the future
-
8:54
ft596: ipsc-derived car-nk cells with engineered persistence for b-cell malignancies
-
2:56
novel drugs for myeloma thromboprophylaxis
-
2:25
novel ai model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
-
2:11
novel approaches in hl
-
5:19
the current treatment landscape for multiple myeloma and trials investigating novel combinations
-
2:55
novel combinations with ruxolitinib being investigated for myelofibrosis
-
1:11
results and rational behind breakthrough therapy-designated e-selectin antagonist for aml
-
1:25
the potential benefits of epigenetic therapy research
-
1:39
the need for disease-modifying therapies in mpns
-
5:08
insights into the tarmac study: time-limited ibrutinib and tisa-cel in patients with r/r mcl
-
4:45
phase ib/ii multi-arm study of combinations of novel agents in r/r aml
-
1:27
the role of menin inhibitors in the treatment of hr-mds and aml
-
3:24
novel agents for the management of r/r myeloma